Table 2.
Actionable targets identified by molecular profiling in the study cohort.
| Target | Number of patients out of total evaluable patients (n/N) | Frequency, % |
|---|---|---|
| Identified by IHC | ||
| Negative/low TS | 9/12 | 75 |
| Negative/low ERCC1 | 6/12 | 50 |
| High TOPO1 | 6/13 | 46 |
| High SPARC∗ | 4/11 | 36 |
| Low MGMT | 3/14 | 21 |
| High TOP2A | 2/11 | 18 |
| Positive AR | 2/14 | 14 |
| Positive ER/PgR | 2/14 | 14 |
| Positive HER2 | 0/14 | 0 |
| Identified by microarray analysis | ||
| KIT overexpression | 4/6 | 67 |
| TOP2B overexpression | 4/6 | 67 |
| PDGFRA overexpression | 3/6 | 50 |
| PDGFRB overexpression | 3/6 | 50 |
| TOP2A overexpression | 3/6 | 50 |
| TYMS overexpression | 2/6 | 33 |
| VDR overexpression | 2/6 | 33 |
| ESR1 overexpression | 2/6 | 33 |
| SPARC overexpression | 2/6 | 33 |
| MGMT underexpression | 2/6 | 33 |
∗SPARC was considered high if either of the SPARC assays (using monoclonal or polyclonal anti-SPARC antibodies) was positive.
AR: androgen receptor; ER: estrogen receptor; ERCC1: excision repair cross-complementation 1; ESR1: estrogen receptor 1; HER2: human epidermal growth factor receptor 2; IHC: immunohistochemistry; MGMT: O-6-methylguanine-DNA methyltransferase; PDGFRA/B: platelet-derived growth factor receptor alpha/beta; PgR: progesterone receptor; SPARC: secreted protein acidic and rich in cysteine; TOPO1: topoisomerase I; TOP2A/B: topoisomerase IIA/B; TS/TYMS: thymidylate synthase; VDR: vitamin D receptor.